Knowthestock.com
CGIX - Cancer Genetics, Inc.

Sell

Weak GrowthEarnings/Profit is Negative

13%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 42.89%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -17.53%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 0.71
Debt Ratio is 0.57
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Cancer Genetics, Inc. (CGIX) - http://www.cancergenetics.com
Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomarker solutions, bio repository solutions, consulting, cytogenetic testing, nucleic acid extraction and purification, flow cytometry, Focus: NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ.
Exchange - NASDAQ
Industry - Medical Specialties
Sector - Health Technology
CEO - John A. Roberts
Employees - 110
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.